1
|
Reineke R, Gembruch U, Geipel A. Fetal thyrotoxicosis after total thyroidectomy due to Graves' disease. Arch Gynecol Obstet 2023; 308:1885-1886. [PMID: 37097313 PMCID: PMC10579105 DOI: 10.1007/s00404-023-06994-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 03/01/2023] [Indexed: 04/26/2023]
Affiliation(s)
- R Reineke
- Department of Obstetrics and Prenatal Medicine, University of Bonn, Bonn, Germany.
| | - U Gembruch
- Department of Obstetrics and Prenatal Medicine, University of Bonn, Bonn, Germany
| | - A Geipel
- Department of Obstetrics and Prenatal Medicine, University of Bonn, Bonn, Germany
| |
Collapse
|
2
|
Gómez-Lavín Fernández L, Comas Rovira M, Pina Pérez S, Moreno Baró A, Corripio Collado R, Zamora Lapiedra M, Lesmes Heredia C, Albert Fabregas L. Management of foetal hyperthyroidism in a mother with autoimmune hypothyroidism: A case report. ENDOCRINOL DIAB NUTR 2023; 70:511-516. [PMID: 37596010 DOI: 10.1016/j.endien.2023.03.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 03/24/2023] [Indexed: 08/20/2023]
Abstract
Foetal hyperthyroidism is mediated by transplacental passage of thyroid stimulating antibodies (TSAbs) and affects mothers with autoimmune (AI) thyroid disease. We report a case of a 33-year-old woman with a history of AI hypothyroidism and raised TSI after 2 stillbirths with suspect foetal hyperthyroidism. At 20.5 gestational weeks (GW) of her third pregnancy, foetal tachycardia and goitre were detected. TSI levels were 30.9mUI/mL. Methimazole (MMI) was started and adjusted based on ultrasound signs (foetal heart rate and thyroid gland vascularisation). The neonate was born at 35GW and cord blood revealed decreased TSH and normal free T4. MMI was started in the neonate at 2 days of life due to the appearance of asymptomatic hyperthyroidism. This case illustrates a rare recurrence of foetal hyperthyroidism in a mother with AI hypothyroidism. Pregestational thyroidectomy, TSAbs determination, early ultrasound diagnosis and foetal therapy helped us to improve obstetric outcomes.
Collapse
Affiliation(s)
- Lucía Gómez-Lavín Fernández
- Obstetrics and Gynaecology Department, Maternal-Foetal Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Inovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
| | - Montserrat Comas Rovira
- Obstetrics and Gynaecology Department, Maternal-Foetal Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Inovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain.
| | - Silvia Pina Pérez
- Obstetrics and Gynaecology Department, Maternal-Foetal Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Inovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
| | - Anna Moreno Baró
- Obstetrics and Gynaecology Department, Maternal-Foetal Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Inovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
| | - Raquel Corripio Collado
- Paediatric Endocrinology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
| | - Marc Zamora Lapiedra
- Obstetrics and Gynaecology Department, Maternal-Foetal Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Inovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
| | - Cristina Lesmes Heredia
- Obstetrics and Gynaecology Department, Maternal-Foetal Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Inovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
| | - Lara Albert Fabregas
- Endocrinology and Nutrition Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell (Barcelona), Spain
| |
Collapse
|
3
|
Ashkar C, Sztal-Mazer S, Topliss DJ. How to manage Graves' disease in women of childbearing potential. Clin Endocrinol (Oxf) 2022; 98:643-648. [PMID: 35192205 DOI: 10.1111/cen.14705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 01/20/2022] [Accepted: 02/08/2022] [Indexed: 11/30/2022]
Abstract
The management of Graves' disease (GD) in women of childbearing potential has multiple specific complexities. Many factors are involved, which differ at the various stages from preconception, conception, first trimester, later pregnancy, postpartum and lactation, with both maternal and foetal considerations. The incidence and significance of the risks incurred from antithyroid drugs (ATDs) in pregnancy have been re-evaluated recently and must be balanced against the risks of uncontrolled hyperthyroidism during childbearing years. Contraception is advised until hyperthyroidism is controlled. ATD cessation should be considered in those who are well controlled on low dose therapy before conception and in early pregnancy. Advice on iodine supplementation does not generally differ in those with GD. Radioiodine (RAI) is contraindicated from 6 months preconception until completion of breastfeeding. In all women who have a history of GD, monitoring of TSH receptor antibodies (TRAb) is strongly recommended during pregnancy, and if elevated, foetal monitoring and assessment of thyroid function in the neonate are required. Of note, RAI increases TRAb for up to a year, making this treatment option even less attractive in this patient group. A small amount of ATD is transferred into breast milk but low doses are safe during lactation. Routine periodic thyroid function testing is recommended in remission to detect postpartum GD recurrence. We present our approach to the Clinical Question 'How to manage GD in women of childbearing potential?'
Collapse
Affiliation(s)
- Claudia Ashkar
- Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia
| | - Shoshana Sztal-Mazer
- Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia
- Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia
- Adjunct Research Fellow, Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - Duncan J Topliss
- Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia
- Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia
| |
Collapse
|